STOCK TITAN

Biodesix, Inc. - BDSX STOCK NEWS

Welcome to our dedicated news page for Biodesix (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodesix 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodesix 's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
Biodesix, Inc.

Nasdaq:BDSX

BDSX Rankings

BDSX Stock Data

143.36M
39.12M
59.44%
13.73%
0.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
BOULDER

About BDSX

biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.